The FDA has cleared Intellia Therapeutics’ Investigational New Drug (IND) application for evaluation of NTLA-2002 for treatment of hereditary angioedema, a rare genetic disorder that includes severe swelling episodes.

NTLA-2002 is an in vivo gene editing candidate that aims to inactivate a gene after a single-dose treatment to the activity of a specific plasma protein.

The phase 1/2 study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-2002 in adults with type I or type II hereditary angioedema.